Richard Struik was born in Hazerswoude in 1972. After several years working as a hospital nurse, the commercial market was getting more of his attention. Richard started his career as account manager at IPSEN. In that role, he was responsible for sales of botulinum toxin on the Benelux market. After 8 years he left IPSEN and became Product Sales manager at Galderma, where he was responsible for both the aesthetic as well as the dermato-oncology market. Richard later took the responsibility as business unit manager at Galderma. In this role, he leads a team of product and sales managers and was P&L-responsible. He was the one achieving reimbursement by getting Metvix (PDT) on the list of expensive medicines. Finally, he leads the launch of both Azzalure (BTX) and Emmervel (HA filler) on the Dutch market. Richard has a strong network in (cosmetic-) dermatology and plastic surgery.
In 2010 he met Henk-Peter and Cees and started to build the esthetics franchise as one of the leading distributor companies in the Benelux area. In June 2013 he became a shareholder of bo medical technologies.